Immunotherapy as a downstaging therapy for liver transplantation.

Schwacha-Eipper, Birgit; Minciuna, Iulia; Banz, Vanessa; Dufour, Jean-François (2020). Immunotherapy as a downstaging therapy for liver transplantation. Hepatology, 72(4), pp. 1488-1490. Wiley 10.1002/hep.31234

Text hep.31234.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (141kB) | Request a copy

Locoregional therapies are downstaging methods for patients with hepatocellular carcinoma (HCC) outside Milan criteria. Sorafenib was the first systemic therapy tested in a neoadjuvant setting of liver transplantation, but with unsatisfactory results due to minimal response rate(1). Recently, immune checkpoint inhibitors have been shown to control HCC in a significant fraction of patients and to even induce complete response (2).

Interest & Impact

Downloads

1 since deposited on 08 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item